Tirzepatide leads to greater average weight loss — 20–22% of body weight compared to semaglutide's 15–17% over 72 weeks. However, both are highly effective, and the best choice depends on individual factors including cost, insurance coverage, side effect tolerance, and overall health goals.
How They Work: Mechanism Comparison
Understanding the mechanistic differences helps explain why these medications produce different results despite both being in the GLP-1 class.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Classification | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| GLP-1 receptor activation | Yes | Yes |
| GIP receptor activation | No | Yes |
| Appetite suppression | Strong | Very strong |
| Insulin sensitivity | Improved | Highly improved |
| Dosing frequency | Once weekly | Once weekly |
Head-to-Head Clinical Data: Direct Comparisons
The most compelling evidence for comparing tirzepatide and semaglutide comes from direct head-to-head trials rather than cross-trial comparisons, which can be misleading due to differences in patient populations, study design, and endpoints.
The SURPASS-2 trial provided the first major head-to-head comparison in patients with type 2 diabetes, randomizing participants to either tirzepatide (at 5mg, 10mg, or 15mg) or semaglutide 1mg. This trial showed that all three tirzepatide doses produced statistically superior reductions in both HbA1c and body weight compared to semaglutide 1mg.
SURMOUNT-5, published in 2024, was the first randomized head-to-head trial directly comparing tirzepatide vs. semaglutide specifically in adults with obesity without diabetes — using the higher weight-management doses (semaglutide 2.4mg vs. tirzepatide up to 15mg) rather than the lower diabetes doses used in SURPASS-2. Tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks in this trial.
Real-world comparative effectiveness data has reinforced the clinical trial findings while adding important nuance. In real-world settings, the weight loss advantage of tirzepatide over semaglutide is somewhat smaller than in controlled trials, likely because real-world dose escalation patterns differ from protocol-driven titration. Many real-world patients do not reach the maximum doses of either medication due to tolerability, cost, or provider preference. Among patients who reach maximum doses of each medication (semaglutide 2.4mg and tirzepatide 15mg), the weight loss difference is most pronounced — tirzepatide patients losing approximately 5–7 additional percentage points of body weight. At lower or moderate doses, the difference narrows to 2–4 percentage points.
It's important to note that individual responses vary considerably for both medications. Some patients achieve exceptional results on semaglutide that exceed the average tirzepatide response, while some tirzepatide patients respond below the semaglutide average. The population-level superiority of tirzepatide does not guarantee that any individual patient will do better on tirzepatide than semaglutide. For patients who are already achieving satisfactory results on semaglutide, switching to tirzepatide solely based on average efficacy data may not be warranted.
Weight Loss Data (72 Weeks)
Recent head-to-head studies and real-world evidence provide clear data on comparative effectiveness.
| Outcome | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Average weight loss | 15–17% | 20–22% |
| ≥10% weight loss | 69% of patients | 89% of patients |
| ≥15% weight loss | 50% of patients | 73% of patients |
| ≥20% weight loss | 32% of patients | 57% of patients |
| ≥25% weight loss | 15% of patients | 36% of patients |
SURMOUNT-5 (2024) — Direct Head-to-Head in Obesity
- Tirzepatide: Mean 20.2% total body weight loss at 72 weeks
- Semaglutide: Mean 13.7% total body weight loss at 72 weeks
- Relative difference: Tirzepatide produced approximately 47% more weight loss
- ≥25% weight loss threshold: 31.6% of tirzepatide patients vs. 16.1% of semaglutide patients
Cost Comparison: What You'll Actually Pay
Cost is often the deciding factor for patients choosing between tirzepatide and semaglutide, and the pricing landscape has shifted meaningfully as shortages resolved and insurance coverage evolved. Understanding both list prices and actual out-of-pocket costs is essential for making an informed decision.
At list prices, semaglutide (Wegovy) is priced at approximately $1,350 per month, while tirzepatide (Zepbound) carries a list price of approximately $1,060 per month. However, very few patients pay list prices. Manufacturer savings programs from both companies can reduce costs substantially for commercially insured patients — both Novo Nordisk and Eli Lilly offer savings cards that can bring copays down to $0–25/month for eligible patients, though these programs have income and insurance requirements that exclude some patients.
Insurance coverage varies significantly between the two medications and between insurance plans. Tirzepatide (Zepbound) has gained coverage on more commercial insurance formularies over time, partly due to its lower list price and partly due to formulary negotiations by Eli Lilly. Semaglutide (Wegovy) coverage is also expanding but remains more restrictive on some plans. Patients should check their specific plan's formulary and prior authorization requirements for both medications before making a decision — in some cases, one medication may be covered while the other is not, making the coverage decision straightforward regardless of efficacy comparisons.
| Option | Semaglutide | Tirzepatide |
|---|---|---|
| Brand list price (monthly) | ~$1,350 (Wegovy) | ~$1,060 (Zepbound) |
| Brand savings card (best case) | As low as $0–25/mo (eligible patients) | As low as $0–25/mo (eligible patients) |
| Luma Health (compounded) | $90/mo flat | $165/mo flat |
| Annual cost (Luma Health) | $1,080/yr | $1,980/yr |
For cash-pay patients who don't qualify for manufacturer savings programs, Luma Health's compounded options at $90/month (semaglutide) and $165/month (tirzepatide) represent the most accessible path to either medication — both delivered through a licensed 503A compounding pharmacy under physician prescription through Wasef Health, PC.
Side Effects Comparison
The side effect profiles of tirzepatide and semaglutide are broadly similar, with gastrointestinal symptoms dominating for both medications. However, there are subtle differences worth noting. Tirzepatide tends to produce slightly higher rates of nausea during the dose escalation phase, which may be related to the additional GIP receptor activation — though the absolute difference is modest (approximately 4 percentage points), and both medications produce similar rates of side-effect-related discontinuation. Semaglutide may produce slightly more constipation, while tirzepatide may produce slightly more diarrhea, though these differences are small and may not be clinically meaningful for most patients. Both medications carry similar warnings regarding pancreatitis, gallbladder disease, and thyroid C-cell tumors based on animal data.
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | 44% | 48% |
| Diarrhea | 30% | 32% |
| Vomiting | 24% | 26% |
| Constipation | 24% | 21% |
| Discontinuation rate | 4–7% | 5–8% |
Who Should Choose Which: A Decision Framework
Rather than declaring one medication universally superior, the most helpful approach is to identify which patient profiles are best served by each medication. This decision framework considers medical factors, practical considerations, and personal preferences.
Patients who need maximum weight loss (BMI over 40 or significant obesity-related comorbidities where every additional percentage point of weight loss matters); patients with type 2 diabetes who need aggressive glycemic control (tirzepatide's dual mechanism produces greater HbA1c reductions); patients whose insurance covers tirzepatide at a lower out-of-pocket cost; and patients who have already tried semaglutide and plateaued or did not achieve their weight loss goal.
Patients who are achieving satisfactory results and should not switch unnecessarily; patients with cardiovascular disease who want the established cardiovascular outcome data from the SELECT trial (semaglutide has the most robust CV outcomes data in patients without diabetes); patients whose insurance covers semaglutide but not tirzepatide; patients who prefer the wider range of available dosage forms (injectable and oral with Rybelsus, or oral semaglutide through Luma Health at $100/month); and patients who have not yet tried a GLP-1 medication and want to start with the agent that has the longest clinical track record.
💡 The bigger factor: For either medication, the most important driver of good results is not which specific agent you choose but rather your ability to maintain consistent treatment, pair the medication with dietary and exercise modifications, and work with a knowledgeable healthcare provider who can optimize dosing and address barriers as they arise.
The Bottom Line
Both tirzepatide and semaglutide are highly effective medications for weight loss and metabolic health. While tirzepatide shows superior weight loss results in clinical trials, both medications can produce meaningful, life-changing outcomes. The best choice depends on individual factors including response to treatment, insurance coverage, cost considerations, and personal health goals. Luma Health offers both as compounded options — $90/month for semaglutide and $165/month for tirzepatide — with clinical oversight through Wasef Health, PC to help determine which is the better fit for your individual profile.
Scientific References
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
- Frías, J.P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. DOI: 10.1056/NEJMoa2107519
Frequently Asked Questions
Tirzepatide produces greater average weight loss — 20–22% in SURMOUNT-1 vs. approximately 15% in STEP 1 for semaglutide. In the SURMOUNT-5 head-to-head trial, tirzepatide showed statistically significantly superior weight loss outcomes compared to semaglutide. However, individual responses vary, and both medications produce clinically meaningful results for the majority of patients.
Luma Health offers compounded semaglutide injectable at $90/month and compounded tirzepatide injectable at $165/month. Oral versions of both are available at $100/month. All prices are all-inclusive with free shipping and same-day to 24–48 hour provider assessment through Wasef Health, PC.
Yes. Your Luma Health clinical team can switch you between medications at any time. No washout period is needed — your provider will typically recommend starting tirzepatide at 2.5mg regardless of your previous semaglutide dose to allow your body to adjust before titrating up.
This depends on your individual goals and budget. At Luma Health, the cost difference between semaglutide ($90/mo) and tirzepatide ($165/mo) is $75/month ($900/year). For patients with significant obesity-related comorbidities where additional weight loss meaningfully changes health outcomes, the premium is often worthwhile. For patients achieving satisfactory results on semaglutide, switching purely for average efficacy data may not be necessary.
Coverage varies significantly by plan and has been expanding over time, particularly for tirzepatide (Zepbound) given its lower list price relative to semaglutide (Wegovy). Check your specific plan's formulary and prior authorization requirements. For patients without coverage or who don't qualify for manufacturer savings cards, Luma Health's compounded options ($90–$165/month) are a significantly more affordable cash-pay alternative.